Thanks for posting Kelsee. Add on to that list BIO Europe November 5-7, 2018; Copenhagen, Denmark and that completes the H2 2018 event list to my knowledge.

Approaching the 3-year anniversary of BETonMACE initiation of screening on 10/26 and of first randomization/dosing on 11/11. Looking forward most to seeing the complete baseline data on the whole BETonMACE population at AHA. This will give us a very good idea of the baseline risk in these patients based on HDL-C, apo-AI, fasting glucose, fasting insulin, HbA1c, LDL-C (and other apoB related measures), TG, eGFR, AP, hsCRP, etc.

At some point, the dam has to break and the media/press/analyst coverage of this has to open up. CVOT trials with imminent results are not known for flying under the radar. I expect sometime between AHA and the announcement of reaching 250 3-point MACE events &  completion of dosing (~end of year) for the dam to crack and the news/analyst coverage to start flowing. How this affects the share price.....TBD.

BDAZ